<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153009">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871090</url>
  </required_header>
  <id_info>
    <org_study_id>60047158</org_study_id>
    <nct_id>NCT01871090</nct_id>
  </id_info>
  <brief_title>Remote Device Interrogation In The Emergency Department</brief_title>
  <acronym>REMEDY</acronym>
  <official_title>Remote Device Interrogation In The Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, post market, non-randomized study to evaluate the reduction in time to
      interrogation for patients with St. Jude Medical remote care compatible devices interrogated
      by the unpaired Merlin@home transmitter in the Emergency Department (ED).  Two sites will
      enroll up to 100 patients total.

      Expected duration of the study is 6 months.  Once enrolled the patient will participate in
      the study for the duration of the Emergency Department stay, until discharged or admitted to
      the hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Time to Interrogation</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to interrogation is defined as the time from Triage (decision to interrogate the device) until the first of: Completion of interrogation, Time of Clinical/Treatment decision, or Emergency Department check out time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical/Treatment Decision</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the time from the Emergency Department Check In Time until the first of:  Time of Clinical/Treatment Decision or Emergency Department Check Out Time (discharged/leaves Emergency Department or admitted to hospital).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Emergency Department Stay</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the time from the Emergency Department Check In Time until the Emergency Department Check Out Time (discharged/leaves Emergency Department or admitted to hospital).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Heart Failure</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <arm_group>
    <arm_group_label>Interrogation with unpaired remote monitoring transmitter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interrogation with programmer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Interrogation with programmer according to usual standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unpaired remote monitoring transmitter</intervention_name>
    <arm_group_label>Interrogation with unpaired remote monitoring transmitter</arm_group_label>
    <other_name>SJM Merlin@home remote monitoring transmitter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Present to Emergency Department with an implanted pacemaker or defibrillator.

          2. Are 18 years of age or older, or of legal age to give informed consent specific to
             state law.

          3. Are willing and able to provide informed consent for study participation.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Girsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute at Harbor - UCLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor - UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Girsky, MD</last_name>
      <phone>310-222-2515</phone>
      <email>marc@drgirsky.com</email>
    </contact>
    <investigator>
      <last_name>Marc Girsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Healthcare System</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Neuenschwander, MD</last_name>
      <phone>740-404-3817</phone>
      <email>jim.neuen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>James Neuenschwander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remote Monitoring</keyword>
  <keyword>Remote Care</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>Pacemaker</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
